News & Views | Published:

Therapeutic antibody gene transfer

Subjects

AAV vectors containing the combined furin-site and 2A 'self-cleaving' peptide facilitate high-level expression of monoclonal antibodies in vivo.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Fang, J. et al. Nat. Biotechnol. 23, 584–590 (2005).

  2. 2

    Lobo, E.D., Hansen R.J. & Balthasar J.P. J. Pharm. Sci. 93, 2645–2668 (2004).

  3. 3

    Flotte, T.R. Gene Ther. 11, 805–810 (2004).

  4. 4

    de Felipe, P. Genet. Vaccines & Ther. 2, 13 (2004).

  5. 5

    de Felipe, P. & Ryan, M.D. Traffic 5, 616–626 (2004).

  6. 6

    Gaken, J. et al. Gene Ther. 7, 1979–1985 (2000).

  7. 7

    Gao, G.-P. et al. Proc. Natl. Acad. Sci. USA 99, 11854–11859 (2002).

  8. 8

    Nakai, H. et al. J. Virol. 79, 214–224 (2005).

  9. 9

    Jooss, K. & Chirmule, N. Gene Ther. 10, 955–963 (2003).

Download references

Author information

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Publication history

  • Issue Date

DOI

https://doi.org/10.1038/nbt0505-551

Further reading

Figure 1: Pathway to therapeutic antibody gene transfer.

Bob Crimi